posted
SYMBA needs to be put on the radar!! Phase III trials, the market potential in breast cancer is huge!
FRAMINGHAM, MA--(MARKET WIRE)--Aug 9, 2006 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) announced that it anticipates closing the enrollment of its IoGen(TM) Phase III pivotal pain study by year-end. The ongoing IoGen study has over 25 active sites across the United States. Symbollon is planning to conduct a comprehensive advertising campaign during the remainder of 2006 to assist these sites in recruiting subjects for the study by yearend. With enrollment completed by yearend, Symbollon expects to announce the study results in the summer of 2007.
Posts: 173 | From: Mississippi | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
